Imunon, INC Form 4 insider transactions

Director Frederick J. Fritz acquired stock options in Imunon, Inc. in lieu of cash compensation for board fees.

Imunon's President and CEO, Stacy Lindborg, reports the acquisition of stock options in the company.

Michael H. Tardugno, Executive Chairman of Imunon, Inc., was granted stock options in lieu of a cash payment on September 6, 2024.

Khursheed Anwer, Chief Scientific Officer of Imunon, Inc., reports the acquisition of stock options in lieu of cash payment increases.

Imunon's President and CEO, Stacy Lindborg, recently purchased 25,000 shares of Imunon common stock on the open market, increasing her direct holdings in the company.

Michael Tardugno, Executive Chairman of Imunon, Inc., purchased 25,000 shares of Imunon common stock on the open market on August 15, 2024.

Michael H. Tardugno, Executive Chairman of Imunon, Inc., acquired 100,000 stock options at an exercise price of $1.22 on June 12, 2024.

Imunon's CEO, Stacy Lindborg, was granted stock options to purchase 112,500 shares of common stock at an exercise price of $1.22 on June 12, 2024.

Khursheed Anwer, Chief Scientific Officer of Imunon, Inc., reports the acquisition of stock options.

Director Frederick J. Fritz acquired stock options for 3,500 shares of Imunon, Inc. at an exercise price of $1.22 on June 12, 2024.

Christine A. Pellizzari, a director of Imunon, Inc., acquired stock options on June 12, 2024.

Director James E. Dentzer acquired stock options in Imunon, Inc. on June 12, 2024.

Director Donald P. Braun acquired options to purchase 3,500 shares of Imunon, Inc. common stock at an exercise price of $1.22 on June 12, 2024.

Imunon's CEO, Stacy Lindborg, reported the acquisition of stock options exercisable for 112,500 shares of common stock.

Jeffrey Wayne Church, CFO of Imunon, Inc., reports the acquisition of stock options.

Khursheed Anwer, Chief Scientific Officer of Imunon, Inc., reports acquisition of stock options.

Michael H. Tardugno, Executive Chairman of Imunon, Inc., acquired stock options exercisable for 12,500 shares of common stock on March 15, 2024.

Director Frederick J. Fritz acquired stock options for 3,500 shares of Imunon, Inc. at an exercise price of $0.86 on March 15, 2024.

Donald P. Braun, a director of Imunon, Inc., acquired options to purchase 3,500 shares of Imunon common stock at an exercise price of $0.86 on March 15, 2024.

Christine A. Pellizzari, a director of Imunon, Inc., acquired stock options exercisable for 4,500 shares of common stock at a price of $0.86 on March 15, 2024.

Director Stacy Lindborg reports the acquisition of stock options in Imunon, Inc.

Director James E. Dentzer acquired stock options in Imunon, Inc. on March 15, 2024.